7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionDigestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 22026-10-08NCT05519475
A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationArrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorderActive, not recruitingPhase 32026-09-25NCT05757869
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, colitis, colonic disorder, digestive system disorder, gastroenteritis, immune system disorder, inflammatory bowel disease, intestinal disorder, ulcer disease, ulcerative colitisRecruitingPhase 22026-09-21NCT07513181
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisAcute Gastroenteritis; Norovirus Acute GastroenteritisActive, not recruitingPhase 32026-05-13NCT06592794
To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy AdultsClostridoides Difficile Associated DiseaseActive, not recruitingPhase 1 / Phase 22026-04-29NCT05805826
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult WomenBone Diseases, Metabolic, Nutritional and Metabolic Diseases, bone disorder, metabolic disease, musculoskeletal system disorder, osteoporosisActive, not recruitingPhase 42026-04-09NCT05303636
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic SteatohepatitisDigestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver diseaseActive, not recruitingPhase 22025-04-18NCT05979779